|Dr. Paulus A. Stoffels M.D., Ph.D.||CEO, Chairman, Interim Head of R&D||986.21k||N/A||1962|
|Mr. Michele Manto M.B.A.||Chief Commercial Officer||636.73k||N/A||1973|
|Mr. Thad Huston||CFO & COO||N/A||N/A||1970|
|Ms. Sofie Van Gijsel||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Valeria Cnossen||General Counsel||N/A||N/A||N/A|
|Marieke Vermeersch||Head of Corporate Communication||N/A||N/A||N/A|
|Ms. Annelies Missotten||Chief Human Resources Officer||N/A||N/A||N/A|
|Ms. Ellen Van Der Aar||Head of Development||N/A||N/A||N/A|
|Mr. Philippe Alen||Senior VP & Head of Business Development||N/A||N/A||N/A|
|Mr. Dirk De Naeyer||Head of Development Operations||N/A||N/A||N/A|
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Galapagos NV’s ISS governance QualityScore as of 28 November 2023 is 6. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 1; Compensation: 10.